Abstract
Thymoquinone (TQ) has been proved to exert wide‐ranging pharmacological activities, with anti‐inflammatory, antioxidant, anticonvulsant, antimicrobial, anti‐tumor, and antidiabetic properties. In this study, we investigated the beneficial effects of TQ on a high‐fat diet (HFD)‐induced nonalcoholic fatty liver disease (NAFLD) in C57BL/6 N mice in vivo and free fatty acid (FFA)‐induced human hepatocellular carcinoma HepG2 cells in vitro. Further, the underlying mechanisms of TQ to promote hepatic autophagy were also discovered. Data showed that TQ caused (p < 0.01) body weight reduction, improved glucose homeostasis, alleviated hepatosteatosis, and decreased hepatic lipid accumulation related to the induction of autophagy in HFD‐fed mice. In vitro, TQ obviously increased (p < 0.01) autophagic flux in FFA‐induced HepG2 cells and consequently reduced the lipid accumulation in combination with activation of AMPK/mTOR/ULK1 signaling pathways. Moreover, pharmacological inhibition of the AMPK pathway by addition with AMPK inhibitor Compound C (CC) or silence of ULK1 by transfection with siRNA(ULK1) into HepG2 cells reversed these beneficial effects of TQ on triggering hepatic autophagy and reducing lipid accumulation (p < 0.01). Taken together, these results suggested that TQ alleviated hepatic lipid accumulation by triggering autophagy through the AMPK/mTOR/ULK1‐dependent signaling pathway. Our study supports a potential role for TQ in ameliorating NAFLD.

This publication has 61 references indexed in Scilit: